Furthermore, while a positive correlation was detected between LBP and HAMP and neutrophil numbers in the placebo group, this association was not present in patients treated with tocilizumab, which suggests that the decline in these markers could be directly linked to the neutropenia observed during anti–IL‐6 therapy. This evidence concerns the gene LBP and neutropenia.